Drug intelligence / Profile preview

BPG-0812

Development stage: Preclinical
Lead developer: Berg
Modality: Small Molecules

Overview

BPG-0812 is a small molecule drug candidate developed by BPGbio, Inc. It targets the ubiquitin-proteasome pathway, specifically acting as a UBE2K discharge inhibitor. This mechanism is aimed at reducing toxic protein aggregates associated with Huntington's Disease by modulating the activity of the E2 ubiquitin-conjugating enzyme UBE2K.

Targets

UBE2K (Ubiquitin-conjugating enzyme E2 K)

Beyond the preview

Go deeper on BPG-0812.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPG-0812.

Explore the full profile